Cargando…

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A

Tumor necrosis factor (TNF) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA). JNJ-61178104 is a novel human anti-TNF and anti-IL-17A monovalent, bispecific antibody that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Songmao, Shen, Fang, Jones, Brian, Fink, Damien, Geist, Brian, Nnane, Ivo, Zhou, Zhao, Hall, Jeff, Malaviya, Ravi, Ort, Tatiana, Wang, Weirong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531573/ https://www.ncbi.nlm.nih.gov/pubmed/32544369 http://dx.doi.org/10.1080/19420862.2020.1770018

Ejemplares similares

A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model
por: Zheng, Songmao, et al.
Publicado: (2020)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
por: Brahmer, Julie R., et al.
Publicado: (2020)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?
por: Zheng, Songmao, et al.
Publicado: (2022)

A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A
por: Xu, Tianshu, et al.
Publicado: (2017)

Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-γ Agonist
por: Clarke, Holly J., et al.
Publicado: (2008)

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2022)

A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells
por: Karami, Neda, et al.
Publicado: (2022)

Cancer immunomodulation using bispecific aptamers
por: Thomas, Brian J., et al.
Publicado: (2022)

Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling
por: Gesiorowski, Annika, et al.
Publicado: (2023)

Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding
por: Zwolak, Adam, et al.
Publicado: (2017)

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models
por: DeAngelis, Nikki, et al.
Publicado: (2022)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
por: Salvadore, Giacomo, et al.
Publicado: (2020)

Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813
por: Lavreysen, Hilde, et al.
Publicado: (2015)

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)
por: Vandenbossche, Joris, et al.
Publicado: (2022)

1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005
por: Martinon-Torres, Federico, et al.
Publicado: (2018)

MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR-γ Agonist Lowers Triglyceride Independently of PPAR-α Activation
por: Chandalia, Apurva, et al.
Publicado: (2009)

Tumor Necrosis Factor α and Interleukin 1β Enhance the Cortisone/Cortisol Shuttle
por: Escher, Geneviève, et al.
Publicado: (1997)

Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation
por: Bonaventure, Pascal, et al.
Publicado: (2017)

Opposite Effects of Mepyramine on JNJ 7777120-Induced Amelioration of Experimentally Induced Asthma in Mice in Sensitization and Provocation
por: Beermann, Silke, et al.
Publicado: (2012)

A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia
por: Covington, Paul S., et al.
Publicado: (2013)

In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
por: Verstraete, Maud, et al.
Publicado: (2015)

Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor
por: Lavreysen, Hilde, et al.
Publicado: (2015)

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
por: Mancuso, Renzo, et al.
Publicado: (2019)

Dataset of eyeblink conditioning in mice treated with the selective mGluR1 antagonist JNJ16259685
por: Tohyama, Shoichi, et al.
Publicado: (2023)

JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
por: Pawar, Jogendra Singh, et al.
Publicado: (2023)

PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury
por: Holmes-Hampton, Gregory P., et al.
Publicado: (2023)

Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding
por: Zwolak, Adam, et al.
Publicado: (2017)

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study( )
por: O’Neil, Brian, et al.
Publicado: (2020)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis
por: Wilson, Simon J, et al.
Publicado: (2019)

Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821)
por: Kumar, Vidya P., et al.
Publicado: (2022)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
por: Azria, D, et al.
Publicado: (2003)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7ni3d972sgqdktdrrbig5lqemu